CPA
RLAY icon

Capital Performance Advisors’s Relay Therapeutics RLAY Stock Holding History

Capital Performance Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11
Closed -$78 – 2131
2024
Q3 		$78 Buy
+11
New +$82 ﹤0.01% 2741

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Capital Performance Advisors's RLAY Position: Q4 2024 in Review

Capital Performance Advisors sold out of Relay Therapeutics (RLAY) in Q4 2024, closing a stake of 11 shares — an estimated $78 sold.

Capital Performance Advisors first reported a position in RLAY in Q3 2024 and held it in 1 quarter. The position peaked at $78 in Q3 2024. 199 funds tracked by Wall St. Rank hold RLAY as of Q4 2024.

  • Capital Performance Advisors reported no remaining Relay Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 11 Relay Therapeutics shares in Q4 2024, an estimated $78.
  • Capital Performance Advisors first reported a position in Relay Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Relay Therapeutics position peaked at $78 in Q3 2024.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.